FDA approves first single-dose antimalarial
Sign Up to like & getrecommendations! Published in 2018 at "Nature Biotechnology"
DOI: 10.1038/nbt0918-785a
Abstract: On July 20, the US Food and Drug Administration approved GlaxoSmithKline’s Krintafel (tafenoquine), a single-dose treatment to prevent relapses of Plasmodium vivax, a malaria parasite that causes more than eight million infections annually. “This drug… read more here.
Keywords: malaria parasite; krintafel; drug; blood ... See more keywords